Use of polypeptide req in preparing a medicament for treating acute stroke
By inhibiting the ubiquitination and degradation of MFSD2a through the peptide REQ, the problem of neurological damage caused by blood-brain barrier disruption in acute stroke was solved, achieving a significant neuroprotective effect.
Patent Information
- Application Number
- CN202410280021.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-12
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2044-03-12
AI Technical Summary
Current treatments for acute stroke are ineffective in alleviating neurological damage, and disruption of the blood-brain barrier leads to persistent neurological injury, with a lack of effective neuroprotective agents.
The peptide REQ is used to reduce the disruption of the blood-brain barrier by preventing the ubiquitination and degradation of MFSD2a. The dosage is 40 mg/kg. The peptide REQ is the intracellular fragment REQREPYEAQ of the cotransporter superfamily domain protein 2a (MFSD2A). It inhibits the expression of developmentally downregulated gene 4-2 (NEDD4-2) in neural progenitor cells and maintains the integrity of the blood-brain barrier.
It significantly reduces cerebral infarction volume, improves neurological function scores, and alleviates neurological damage in acute stroke, demonstrating a significant neuroprotective effect.
Smart Images

Figure CN118105465B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical technology, specifically to the application of a polypeptide REQ in the preparation of drugs for treating acute stroke. Background Technology
[0002] Stroke is the second leading cause of death worldwide and a major cause of death in China. Ischemic stroke accounts for 60-70% of all strokes, characterized by high morbidity, high mortality, and high disability rates, posing a significant public health problem. Currently, revascularization is often achieved clinically using intravenous rt-PA thrombolysis combined with mechanical thrombectomy. However, the presence of ischemia-reperfusion injury means that even if revascularization is performed within the time window, it cannot effectively alleviate neurological damage. Therefore, the development of novel neuroprotective agents to reduce neurological injury is of great significance.
[0003] The blood-brain barrier (BBB) is the interface that precisely regulates the distribution of substances between the central nervous system (CNS) and the circulatory system. After a stroke, the BBB is disrupted, leading to persistent neurological damage, and its repair is crucial for post-stroke brain injury recovery. Therefore, inhibiting BBB disruption is a well-defined target for neuroprotective therapy.
[0004] Mfsd2a is defined as a sodium-dependent lysylcholine cotransporter. Highly expressed in endothelial cells and widely distributed in the blood-brain and blood-retinal barriers, it has recently been shown to be crucial for the formation and function of the blood-brain barrier (BBB). Aberrant degradation of Mfsd2a often leads to BBB dysfunction and subsequent neurological damage. Reversing the aberrant reduction of Mfsd2a is a highly promising strategy for protecting the BBB and mitigating neurological injury. Therefore, Mfsd2a is an attractive target for modulating BBB permeability and a potential therapeutic target for central nervous system pathologies.
[0005] Previous studies have found that ubiquitination is a major pathway for Mfsd2a degradation. Truncation of different peptides in the intracellular segment of Mfsd2a is one strategy to inhibit its ubiquitination and degradation. However, peptides are often metabolized rapidly, making it difficult to produce effects in vivo. Summary of the Invention
[0006] The purpose of this invention is to provide an application of the polypeptide REQ in the preparation of a drug for treating acute stroke. The drug of this invention can prevent the ubiquitination and degradation of MFSD2a and reduce the damage to the blood-brain barrier.
[0007] The technical solution of this invention is: Application of the peptide REQ in the preparation of drugs for treating acute stroke.
[0008] The amino acid sequence of the polypeptide is shown in SEQ ID NO:1.
[0009] The drug in question is an inhibitor.
[0010] The peptide REQ reduces ubiquitination in cells overexpressing the cotransporter superfamily domain protein 2a.
[0011] The drug is used for neuroprotection after acute stroke.
[0012] The dosage of the drug is 40 mg / kg.
[0013] The polypeptide described in this invention is an intracellular fragment of the cotransporter superfamily domain 2a (MFSD2A): (278-287) REQREPYEAQ (SEQ ID NO:1), which has a significant neuroprotective effect after stroke. The polypeptide described in this invention is a protein-protein interaction inhibitor of cotransporter superfamily domain 2a (MFSD2A) and the neural progenitor cell downregulated gene 4-2 (NEDD4-2), thereby preventing the ubiquitination and degradation of MFSD2a and reducing blood-brain barrier disruption.
[0014] The cotransporter superfamily domain protein 2a (MFSD2A) is a sodium-dependent lysophosphatidylcholine cotransporter that plays a crucial role in maintaining the integrity of the blood-brain barrier and neurological function. Aberrant degradation of MfSD2A often leads to blood-brain barrier dysfunction, while upregulation of MfSD2A can reverse neurological damage. Neural progenitor cell expression of developmentally downregulated gene 4-2 (NEDD4-2) belongs to the NEDD4 family of E3 ubiquitin ligases. Previous studies have reported that MfSD2A can be specifically recognized and ubiquitinated by neural progenitor cell expression of developmentally downregulated gene 4-2 (NEDD4-2), and ultimately degraded via the protease pathway.
[0015] The applicant's experimental verification showed that the peptide REQ has in vivo activity and can reduce Mfsd2a ubiquitination degradation at a dose of 40 mg / kg. The peptide REQ has a significant neuroprotective effect in acute cerebral infarction. Intraperitoneal injection of the peptide after infarction can significantly reduce the infarct volume and show significant differences in neurological function scores (Longa score), indicating that it reduces post-cerebral infarction damage in a behavioral sense.
[0016] The polypeptide REQ described in this invention exerts a neuroprotective effect in an in vivo model of acute ischemic stroke. Attached Figure Description
[0017] Figure 1 Longa behavioral score after peptide treatment in a mouse MCAO model; Figure 2 The infarct volume after peptide treatment in a mouse MCAO model; Figure 3 For the purpose of Western blotting of peptide interactions, the changes in Mfsd2a ubiquitination in GFP-293T cells with high or no expression of Mfsd2a were analyzed, with WW3 ligand peptide-UGR1 selected as a control. Detailed Implementation
[0018] To make the technical problems, technical solutions and advantages of the present invention clearer, a detailed description will be given below in conjunction with the accompanying drawings and specific embodiments.
[0019] Unless otherwise specified, all reagents used in this embodiment are of analytical grade, and the progress of all chemical reactions is detected by thin-layer chromatography.
[0020] To demonstrate the neuroprotective effect of the peptide in acute stroke, the applicant used the internationally recognized and most widely used middle cerebral artery occlusion (MCAO) model (focal ischemic stroke model), a commonly used model to simulate human ischemic acute stroke and recanalization.
[0021] The polypeptides involved in this embodiment were synthesized by Qiangyao Biotechnology Co., Ltd., with a purity greater than 98%; the lyophilized polypeptide powder was prepared with physiological saline to the required concentration for intravenous injection.
[0022] 1.1 Laboratory Animals and Grouping SPF-grade male C57BL / 6 mice weighing 20-24 g (Speford (Beijing) Biotechnology Co., Ltd.) were selected and randomly divided into 3 groups after one week of acclimatization: sham operation group (Sham group), model group (vehicle group), and drug administration group (REQ 40 mg / kg group).
[0023] 1.2 Establishment of mouse MCAO model and peptide treatment A. Mouse MCAO modeling using the suture occlusion method: Male C57BL / 6J mice were anesthetized with sodium pentobarbital (Merck) (60 mg / kg). After an incision along the midline of the neck, the left common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were carefully exposed under a surgical microscope. Subsequently, a silicone-coated nylon suture was introduced into the ECA and advanced along the ICA to block the origin of the middle cerebral artery (MCA). After 90 minutes, the suture was withdrawn to restore blood flow (reperfusion). The peptide REQ was dissolved using ddH2O. Each group of mice was injected with 40 mg / kg of the peptide via tail vein, while the solvent group received an equal volume of solvent. Throughout the procedure, the animals' body temperature was maintained at 37.0 ± 0.5 degrees Celsius.
[0024] B. Sham surgery: The MCAO model in mice was established using the suture occlusion method. The procedure was as follows: Male C57BL / 6J mice were anesthetized with sodium pentobarbital (Merck) (60 mg / kg). After incision along the midline of the neck, the left common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were carefully exposed under a surgical microscope. Throughout the procedure, the animals' body temperature was maintained at 37.0 ± 0.5 degrees Celsius.
[0025] Longa scores were performed on mice 24 hours post-surgery in steps A and B (see [link]). Figure 1 Scoring criteria: ① No neurological deficits: 0 points; ② The forepaw on the paralyzed side cannot be fully extended: 1 point; ③ The animal turns in circles towards the paralyzed side when walking: 2 points; ④ The animal leans towards the paralyzed side when walking: 3 points; ⑤ The animal cannot walk automatically and exhibits loss of consciousness: 4 points.
[0026] Data were processed using Prism 8 software. Comparisons with the Vehicle group were performed using one-way ANOVA (p < 0.005) and Tukey's test. Figure 1 It is evident that the mice's motor abilities were significantly restored after using the peptides.
[0027] 1.3 TTC staining and analysis Mice with MCAO modeling were sacrificed 24 h after reperfusion and their brains were harvested. After slightly hardening at -80 °C, coronal sections were sequentially sectioned posteriorly, with a section thickness of 2 mm. The sections were then immersed in 2% TTC solution and incubated at 37 °C in the dark for 15 min, with the sections being turned every 5 min to ensure uniform staining. After incubation, the TTC solution was discarded, and the sections were fixed with 4% paraformaldehyde for 24 h. Images were then taken, and the ischemia level was statistically analyzed using ImageJ software.
[0028] The results showed that the peptides significantly reduced the infarct volume in the brain of MCAO model mice, exhibiting neuroprotective effects (see [link to study]). Figure 2 ).
[0029] The peptide REQ and WW3 ligand peptide-UGR1 will be added to 293T cells (Donghuan Bio) that stably express Mfsd2a-GFP. (For specific methods, please refer to Castillo, Francisco et al. “Phage display identification of nanomolar ligands for human NEDD4-WW3: Energetic and dynamic implications for the development of broad-spectrum antivirals.”) International journal of biological macromolecules vol. 207 (2022): 308-323. doi:10.1016 / j.ijbiomac.2022.03.010) served as a control, while 293T cells stably expressing GFP served as a reference for stable expression of Mfsd2a-GFP. Equal volumes of 293T cell lysates were analyzed by Western blot using ubiquitin (CST, 3936S) antibody. The results showed that the peptide REQ reduced ubiquitination degradation in a dose-dependent manner (see [reference missing]). Figure 3 ).
[0030] sequence list SEQ ID NO:1 REQREPYEAQ.
Claims
1. The application of the polypeptide REQ in the preparation of a drug for treating acute stroke, wherein the amino acid sequence of the polypeptide is shown in SEQ ID NO:
1.
2. The application according to claim 1, characterized in that: The drug in question is an inhibitor.
3. The application according to claim 2, characterized in that: The peptide REQ reduces ubiquitination in cells overexpressing the cotransporter superfamily domain protein 2a.
4. The application according to claim 1, characterized in that: The drug is used for neuroprotection after acute stroke.
5. The application according to claim 1, characterized in that: The dosage of the drug is 40 mg / kg.
Citation Information
Patent Citations
Full-length cDNA sequences
EP1308459A2
